['diabetes mellitus, type 2', 'hypertension']
['iw-1973', 'placebo']

        Inclusion Criteria:

          -  Patient is ambulatory male or female

          -  Patient's body mass index score is > 20 and < 40 kg/m^2 at the Screening Visit

          -  Women of childbearing potential must have a negative pregnancy test at the time of
             screening and check-in and must agree to use protocol-specified contraception
             throughout the duration of the study

          -  Patient's health is stable with no clinically significant findings on physical
             examination

          -  Patient has type 2 (ie, adult onset) diabetes mellitus diagnosed by a physician or
             nurse practitioner > 6 months before the Screening Visit, is on a stable glycemic
             control medication, and protocol specified hemoglobin (Hb)A1c values at the Screening
             Visit

          -  Patient has hypertension diagnosed by a physician or nurse practitioner > 6 months
             before the Screening Visit, and blood pressure (BP) within the protocol's acceptable
             range

          -  Patients must be on a stable regimen for hypertension control that includes an
             angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB),
             stable for 28 days

          -  Other inclusion criteria per protocol

        Exclusion Criteria:

          -  Patient has a clinically significant active or unstable medical condition that, in the
             opinion of the Investigator, would preclude trial participation

          -  Patient is on medication(s) that, when co-administered with a sGC stimulator, could
             increase the risk of hypotension

          -  Patient has evidence of severe or active end-organ damage

          -  Patient is an active smoker or has used any nicotine-containing products (cigarettes,
             e-cigarettes, vape pens, cigars, chewing tobacco, gum, patches) during the 6 months
             before Check-in. Use of nicotine is excluded during the study until after the End of
             Trial Visit.

          -  Other exclusion criteria per protocol
      